Literature DB >> 7724661

Coley's toxins, tumor necrosis factor and cancer research: a historical perspective.

B Wiemann1, C O Starnes.   

Abstract

As far back as the 1700s, it was recorded that certain infectious disease processes could exert a beneficial therapeutic effect upon malignancy. Most prominent among the numerous deliberate efforts made to take advantage of these observations was that of a pioneering New York surgeon, William B. Coley, active career 1891-1936. Using a bacterial vaccine to treat primarily inoperable sarcoma. Coley accomplished a cure rate of better than 10%. This review examines the history of these efforts and presents a discussion of their corresponding relevance to present day immunotherapy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7724661     DOI: 10.1016/0163-7258(94)90023-x

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  115 in total

1.  Cytokine anniversary: TNF trailblazers five centuries apart.

Authors:  Claude Libert
Journal:  Nature       Date:  2015-07-09       Impact factor: 49.962

2.  Anti-tumor efficacy of plasmid encoding emm55 in a murine melanoma model.

Authors:  Brittany L Bunch; Krithika N Kodumudi; Ellen Scott; Jennifer Morse; Amy Mackay Weber; Anders E Berglund; Shari Pilon-Thomas; Joseph Markowitz
Journal:  Cancer Immunol Immunother       Date:  2020-06-18       Impact factor: 6.968

Review 3.  Reactive oxygen species in inflammation and tissue injury.

Authors:  Manish Mittal; Mohammad Rizwan Siddiqui; Khiem Tran; Sekhar P Reddy; Asrar B Malik
Journal:  Antioxid Redox Signal       Date:  2013-10-22       Impact factor: 8.401

4.  PDL1 expression is a poor-prognosis factor in soft-tissue sarcomas.

Authors:  François Bertucci; Pascal Finetti; Delphine Perrot; Agnès Leroux; Françoise Collin; Axel Le Cesne; Jean-Michel Coindre; Jean-Yves Blay; Daniel Birnbaum; Emilie Mamessier
Journal:  Oncoimmunology       Date:  2017-02-08       Impact factor: 8.110

Review 5.  Is complement good or bad for cancer patients? A new perspective on an old dilemma.

Authors:  Maciej M Markiewski; John D Lambris
Journal:  Trends Immunol       Date:  2009-05-08       Impact factor: 16.687

Review 6.  The emerging understanding of myeloid cells as partners and targets in tumor rejection.

Authors:  Miranda L Broz; Matthew F Krummel
Journal:  Cancer Immunol Res       Date:  2015-04       Impact factor: 11.151

7.  Innate immune responses induced by CpG oligodeoxyribonucleotide stimulation of ovine blood mononuclear cells.

Authors:  Angelo Mena; Anil K Nichani; Yurij Popowych; Dale L Godson; Donna Dent; Hugh G G Townsend; George K Mutwiri; Rolf Hecker; Lorne A Babiuk; Philip Griebel
Journal:  Immunology       Date:  2003-10       Impact factor: 7.397

8.  TLR4-mediated immunomodulatory properties of the bacterial metalloprotease arazyme in preclinical tumor models.

Authors:  Felipe V Pereira; Amanda C L Melo; Filipe M de Melo; Diego Mourão-Sá; Priscila Silva; Rodrigo Berzaghi; Carolina C A Herbozo; Jordana Coelho-Dos-Reis; Jorge A Scutti; Clarice S T Origassa; Rosana M Pereira; Luis Juliano; Maria Aparecida Juliano; Adriana K Carmona; Niels O S Câmara; Moriya Tsuji; Luiz R Travassos; Elaine G Rodrigues
Journal:  Oncoimmunology       Date:  2016-05-05       Impact factor: 8.110

9.  Sarcoma Tumor Microenvironment.

Authors:  Panagiotis Tsagozis; Jordi Gonzalez-Molina; Anna-Maria Georgoudaki; Kaisa Lehti; Joseph Carlson; Andreas Lundqvist; Felix Haglund; Monika Ehnman
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

Review 10.  Progress and challenges in the vaccine-based treatment of head and neck cancers.

Authors:  Aldo Venuti
Journal:  J Exp Clin Cancer Res       Date:  2009-05-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.